Sign in with Google. Opens in new tab
ENTITY
Astellas Pharma

Astellas Pharma (4503 JP)

155
Analysis
Health CareJapan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia
more
21 Sep 2016 01:03

ANIMAL SPIRITS™ REPORT: Japan Equity Market Outlook - Escaping The Value Trap

Investment Conclusions We are currently "neutral" in our view on Japan in global developed market portfolios but "underweight" in our APAC...

Share
13 Sep 2016 11:39

Japan Stock Market Seasonality - Late Q4 Is Indeed Good

Pelham Smithers came out with a worthwhile comment on the Q4 seasonality of Japanese markets. I agree with their assessment of being bullish Japan...

Logo
355 Views
Share
05 Sep 2016 05:45

Short Sell Research Vs The Japan Stock Market Blob

Two recent press articles "Muddy Waters and Andrew Left: the short sellers having a ball" (...

29 Aug 2016 14:03

Japan Pharma Hits 52 Week Low

The Topix pharmaceutical index (TPPHRM) fell to 2,355 just after the lunch break in Tokyo on Friday 19th August, before recovering to 2,377, with...

bullishAstellas Pharma
23 Aug 2016 22:24

Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm

Pfizer is to pay US$81.50/shr for Medivation, considerably above Sanofi’s original offer of US$52.5bil. This values the Xtandi-originator at...

x